Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIMALAYA: Durvalumab and Tremelimumab as First-line Treatment in Advanced Hepatocellular Carcinoma
2016-005126-11Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Durvalumab + Tremelimumab, Durvalumab Monotherapy and Sorafenib (3 arms). Primary endpoint: Overall survival. Started Sep 2017; status: active.
02
Drugs
durvalumabtremelimumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2016-005126-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005126-11.